Ceramedx offers a natural ceramide therapy system developed for dry, sensitive skin, containing exclusive Riceramide®-3 natural ceramide technology. The products are formulated without irritating fragrances and are clinically tested.

Ceramedx

Ceramedx offers natural ceramide therapy products for dry and sensitive skin, developed in consultation with dermatologists.

Ceramedix, Inc. | 906 followers on LinkedIn. Eliminating Organ Failure with Tissue Protection Therapies | Ceramedix is a growing, privately- and government- funded biopharmaceutical company developing a new class of endothelial tissue protection and repair medicines pioneered by leading scientific and clinical experts in these areas. 

Our scientific founders at Memorial Sloan Kettering Cancer Center in New York and our Chief Scientific Officer have formed a deep, mechanistic understanding of a novel signaling biology that drives tissue injury in a broad range of medically relevant settings.

We believe our drug candidates will have application for treating multiple disease stresses that lead to organ failure, including those that affect the vascular endothelium of the eye, lung, kidney, and other organs.

Partner, Jan Consulting Group, LLP

Lisa Janicki, CPA

Molecular Biologist

Samia Mohammed, PhD

Olivia Beane

Ceramedix, Inc.

BIO 2024 Attending BIO 2024? Click below to send Ceramedix a meeting request in the BIO partnering system! #BIO2024 https://lnkd.in/eCaPdrBR

We're #hiring a new Project Manager in New York, New York. Apply today or share this post with your network.

Metric
Company Name	Ceramedx
Symbol
MSH ID	COM:CERAMEDX
Market	PRIVATE
Sector	Consumer Goods
Industry	Personal Care Products
Country	US
Stage
Employee Count
Website	ceramedx.com
LinkedIn	ceramedix
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	4.87K
Web Traffic Growth	0.77
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CERA

COM:CERAMEDX

Ceramedx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue